Standard BioTools Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-74.9M | $-138.9M | $-74.7M | $-190.1M | $-59.2M | $-53.0M | $-64.8M | $-59.0M |
| Depreciation & Amortization | $9.3M | $12.5M | $12.7M | $12.5M | $3.2M | $4.0M | $4.6M | $5.4M |
| Depreciation | $6.9M | $3.8M | $3.4M | $2.8M | $2.8M | $3.1M | $3.6M | $4.2M |
| Amortization | $1.7M | $4.3M | $11.2M | $11.5M | $11.9M | $11.9M | $11.2M | $11.2M |
| Stock-Based Compensation | $29.6M | $31.7M | $13.1M | $14.9M | $16.1M | $14.5M | $11.4M | $11.0M |
| Net Cash from Operating Activities | $-74.3M | $-143.5M | $-43.3M | $-89.4M | $-44.1M | $-15.4M | $-35.2M | $-25.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $8.3M | $8.4M | $2.8M | $3.8M | $13.3M | $12.7M | $2.5M | $372.0K |
| Business Acquisitions | $0 | $1.4M | $0 | — | $0 | $5.2M | $0 | $0 |
| Net Cash from Investing Activities | $27.4M | $363.2M | $20.2M | $-88.1M | $-11.9M | $40.0M | $-39.3M | $4.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $0 | $40.5M | $5.4M | $563.0K | $0 | — | — | — |
| Net Cash from Financing Activities | $570.0K | $-102.6M | $-6.8M | $230.8M | $16.0M | $20.9M | $2.8M | $57.7M |
| Net Change in Cash | $-45.5M | $116.3M | $-29.8M | $52.9M | $-40.1M | $45.8M | $-71.7M | $37.3M |
| Free Cash Flow | $-82.6M | $-151.8M | $-46.1M | $-93.2M | $-57.3M | $-28.1M | $-37.7M | $-25.6M |